

## PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**  
**(Attorney Docket No. 05-363)**

<b>In the Application of:</b>	)	
	)	
<b>Philip John Hogg</b>	)	
	)	<b>International Appl. No.:</b>
<b>Serial No.: TBA</b>	)	<b>PCT/AU2003/001483</b>
	)	
	)	<b>International Filing</b>
<b>Filed: Herewith</b>	)	<b>Date: November 7, 2003</b>
	)	
<b>For: Induction of the Mitochondrial</b>	)	
<b>Permeability Transition</b>	)	

**INFORMATION DISCLOSURE STATEMENT**

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:


Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. The references are listed on the enclosed PTO Form 1449.

This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. §102 or §103.

Also, enclosed is a copy of the International Search Report in which some of the above-listed references were cited during the prosecution of a corresponding PCT application.

In accordance with MPEP Sections 609 and 707.05(b), it is requested the document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Respectfully submitted,

By:   
Michael S. Greenfield  
Reg. No. 37,142  
**McDonnell Boehnen Hulbert & Berghoff LLP**  
300 South Wacker Drive, Suite 3100  
Chicago, Illinois 60606

Dated: May 9, 2005

FORM PTO-1449  
(Rev. 2-32)U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

05-363

Serial No. 107534922

To Be Assigned

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

## Applicant:

Philip John Hogg

## Filing Date:

Herewith

## Group:

To Be Assigned

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
------------------	-----------------	------	------	-------	----------	----------------------------

## FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes No
/C.S./	A1	WO 00/79274 A	12/28/2000	PCT		X

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

/C.S./	A2	Korge et al., "Phenylarsine oxide induces mitochondrial permeability transition, hypercontracture, and cardiac cell death", <i>Am J. Physiol. Heart Circ. Physiol.</i> , <b>2001</b> , Vol. 280, pp. H2203-H2213.
	A3	Costantini et al., "Modulation of the mitochondrial permeability transition pore by pyridine nucleotides and dithiol oxidation at two separate sites", <i>The Journal of Biological Chemistry</i> , <b>1996</b> , Vol. 271, No. 12, pp. 6746-6751.
	A4	McStay et al., "Role of critical thiol groups on the matrix surface of the adenine nucleotide translocase in the mechanism of the mitochondrial permeability transition pore", <i>Biochem J.</i> , <b>2002</b> , Vol. 367, pp. 541-548.
	A5	Hortelano et al., "Nitric oxide induces apoptosis via triggering mitochondrial permeability transition", <i>FEBS Letters</i> , <b>1997</b> , Vol. 410, pp. 373-377.
	A6	Balakirev et al., "Gradual changes in permeability of inner mitochondrial membrane precede the mitochondrial permeability transition", <i>Archives of Biochemistry and Biophysics</i> , <b>1998</b> , Vol. 356, No. 1, pp. 46-54.
	A7	Costantini et al., "Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition core opening and apoptosis", <i>Oncogene</i> , <b>2000</b> , Vol. 19, pp. 307-314.
	A8	Don et al., "A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells", <i>Cancer Cell</i> , <b>2003</b> , Vol. 3, pp. 497-509.
/C.S./	A9	Al-Nasser, I. A., "In vivo prevention of adriamycin cardiotoxicity by cyclosporin A or FK506", <i>Toxicology</i> , <b>1998</b> , Vol. 131, pp. 175-181.

EXAMINER /Christopher Stone/

DATE CONSIDERED 05/13/2008

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.